The TARGET Model
TARGET provides an easier, more feasible avenue to generate and analyze real-world patient data. The unique foundation of the company, the TARGET model, organizes distinguished disease stakeholders around a common dataset, led by a steering committee of key opinion leaders and an advisory committee of the following participants: industry partners, regulatory authorities, payers, and patient advocacy representatives.
TARGET’s turnkey solution gives partners the ability to rapidly and seamlessly activate new disease communities through longitudinal, observational real-world data registries. With 250+ established site relationships (both community and academic) and a proven framework, TARGET generates quality real-world data in a timely manner and delivers helpful disease insights to support partners’ real-world evidence efforts.
TARGET’s data management and analyses are additionally hosted in-house, which means partners can eliminate the operational hassle of developing or maintaining a disease registry and accessing claims databases. In turn, partners are able to advance development and strategic initiatives with unlimited access to query TARGET’s robust database and can actively participate in shaping the disease registry through an ad hoc advisory board of key stakeholders.
The TARGET model utilizes a multidisciplinary approach that involves thorough research on each disease community from the following committees: academic, advisory and publications.
Academic Steering Committee
Each TARGET disease community begins with the creation of an academic steering committee of disease experts and world-class key opinion leaders to guide protocol development and study design, including the creation of each study’s research plan.
TARGET has advisory committees for each disease that is made up of industry partners, regulatory agency representatives, and patient advocacy groups to strengthen the understandings and challenges of the diseases.
TARGET collaborates with industry partners, Principal Investigators and academic steering committee members to create peer-reviewed abstracts and manuscripts that address scientific gaps in knowledge. TARGET abstracts are presented at national and international scientific conferences and submitted to high-quality peer reviewed journals.
TARGET is committed to ensuring that all activities performed by, or on behalf of, TARGET meet the highest quality/ethical standards and are performed in compliance with applicable regulatory requirements. TARGET has implemented an efficient and effective Quality Management System, with a focus on data quality, in order to provide regulatory-grade data to partners. The TARGET data management and statistics team is responsible for the development and maintenance of the databases for each of our TARGET Communities, as well as the analysis and reporting of the data. TARGET utilizes innovative methodologies for predictive analytics and machine learning, epidemiology, biostatistics, and data visualization to provide robust and informative solutions for our partners’ needs.
TARGET's technology assists community-focused abstractors to review electronic medical records, where much of the health information is captured in an unstructured format. Data is curated according to pre-defined guidelines to maximize consistency and quality of our data. Once entered, numerous edit checks are implemented, and medications and events are coded using medical dictionaries common to the regulatory environment (e.g. MedDRA, WHODRUG). Data of critical importance are further monitored against the source medical records for accuracy, consistent with the community-specific monitoring guidelines.
Patient-Reported Outcome (PRO) Measures
TARGET supplements the data available from medical records with periodic assessments of PRO measures. This includes multiple validated surveys specifically chosen for each disease to elucidate patient well-being and disease status.
TARGET has developed a biorepository of more than 100,000 biospecimen samples that partners can utilize for their own research purposes on a first-come, first-serve basis (blood, serum, and tissue samples). By accessing these samples, partners may conduct various additional studies and testing such as biomarkers and genomics analysis. Given the robust databasing of TARGET’s biorepository, data results can be linked to the longitudinal clinical data for each individual patient.